ArticleBMC cancer2021
Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan.
Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- A comprehensive overview of the molecular features and therapeutic targets in BRAFClinical and translational medicine · 2024Pooled it
- A Systematic Review and Meta-analysis on the Occurrence of Biomarker Mutation in Colorectal Cancer among the Asian Population.BioMed research international · 2022Pooled it
- The Phase II Study of Panitumumab in Chemotherapy-Naïve Frail or Elderly Patients with RAS Wild-type Colorectal Cancer: OGSG 1602 Final Results.The oncologist · 2023Trial
- Prognostic factors of non-metastatic right colon adenocarcinoma: A multicentre retrospective analysis from the ATCCR database.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2026Observational
- A Clinical and Molecular Comparative Analysis of KRAS Exon 2 and KRAS Non-Exon 2 Mutated Colorectal Cancer.Cancers · 2026Article
- MMSA-1 is regulated by Wnt/TCF4 and involved in multiple myeloma progression and invasion via RAS/RAF signaling pathway.Annals of hematology · 2026Article
- Clinical and prognostic characteristics of metastatic colorectal cancer with minorOncology letters · 2025Article
- East meets West: The winning combination againstWorld journal of clinical oncology · 2025Article
- Successful Treatment of Locally Advanced Microsatellite Instability-High Ascending Colon Cancer Using an Immune Checkpoint Inhibitor without Extensive Resection: A Case Report.Surgical case reports · 2025Article
- BRAF mutations and the association of V600E with CD133 and CDX2 expression in a Pakistani colorectal carcinoma cohort.BMC cancer · 2024Article
- Reclassification ofTherapeutic advances in medical oncology · 2024Article
- Clinical research progress on BRAF V600E-mutant advanced colorectal cancer.Journal of cancer research and clinical oncology · 2023Review
- Article
- Is the combination of immunotherapy with conventional chemotherapy the key to increase the efficacy of colorectal cancer treatment?World journal of gastrointestinal oncology · 2023Review
- Case report: administration of immune checkpoint inhibitor for SMARCB1 (INI1)-negative rhabdoid carcinoma with microsatellite instability (MSI)-high in the right colon.Surgical case reports · 2023Article
- Article
- Prognostic Differences of RAS Mutations: Results from the South Australian Metastatic Colorectal Registry.Targeted oncology · 2022Article
- The Prognostic Value of Locoregional Interventions for BRAF V600E Metastatic Colorectal Cancer: A Retrospective Cohort Analysis.Biomolecules · 2021Article
- Clinical Implication of KRAS Mutation Variants in Patients With Resected Colon Cancer.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRAS/BRAF
methodsA total of 152 chemotherapy-naïve patients with mCRC were included in this study between August 2018 and July 2019. Tumor samples were collected, and RAS/BRAF
resultsRAS/BRAF
conclusionsIn our multicenter study, the findings elucidated the clinical and prognostic features of patients with detailed RAS/BRAF
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.